Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04474158 · ClinicalTrials.gov registry record · NA
Creating Peace: Community-based Youth Violence Prevention to Address Racism and Discrimination
A NA study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- NA
- Development phase
- 581
- Enrollment target
NCT04474158: Completed NA study, sponsored by University of Pittsburgh.
NCT04474158 is a NA study that has completed, run by University of Pittsburgh. The registered enrollment target is 581 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (59% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04474158, a NA study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- NA
- Development phase
- 581 participants
- Enrollment target
Study Summary
This cluster-randomized community-partnered study will examine the effectiveness of a trauma-sensitive, gender transformative youth violence prevention program called Creating Peace that integrates racism and discrimination prevention with youth ages 14-19.
Primary Outcome
Summary score of any recent use of violence (physical, sexual, and emotional abuse; sexual violence; physical violence and threatening with a weapon; cyber dating abuse, cyber peer abuse, and sexting) calculated as one point for each behavior then summed (lower score indicates better outcome)
Interventions
- BEHAVIORAL Creating Peace
- BEHAVIORAL Job Readiness
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 581 participants |
| Start Date | 2020-12-04 |
| Est. Completion | 2026-01-25 |
| Phase | NA |
What the finished NCT04474158 record still lists
NCT04474158 is an interventional study that assigns participants to a tested intervention. The registered 581 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (59% lower).
The record links to 0 conditions, and to 2 interventions - of which Creating Peace is the first listed.
NCT04474158 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04474158 about?
NCT04474158 is a clinical study titled "Creating Peace: Community-based Youth Violence Prevention to Address Racism and Discrimination". This cluster-randomized community-partnered study will examine the effectiveness of a trauma-sensitive, gender transformative youth violence prevention program called Creating Peace that integrates racism and discrimination prevention with youth ages 14-19.
What is the current status of trial NCT04474158?
This trial is currently completed. It is a NA study. The enrollment target is 581 participants. The study started on 2020-12-04. Estimated completion is 2026-01-25.
What interventions are being tested in trial NCT04474158?
The interventions under investigation include: Creating Peace (BEHAVIORAL), Job Readiness (BEHAVIORAL).
Who is sponsoring clinical trial NCT04474158?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04474158's enrollment target sits among peer trials
581 177th of 2000 higher than 1,824 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06350097 · 582 participants · Phase 3
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
- NCT06563895 · 582 participants · Phase 3
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
- NCT06819007 · 582 participants · Phase 3
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- NCT04575935 · 580 participants · Phase 3
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI